Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Biopharma dealmaking in 2019

  1. Amanda Micklus

    1. Informa, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Patricia Giglio

    1. Informa, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

In 2019, the biopharma industry continued to be faced with challenges related to drug pricing, but also made major achievements, including advances with novel modalities such as potentially curative gene therapies. Against this backdrop, biopharma dealmaking did not disappoint, with plenty of mergers and partnerships signed.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 19, 87-88 (2020)

doi: https://doi.org/10.1038/d41573-020-00003-5

Updates & Corrections

  • Correction 14 January 2020: The data on the total number and value of mergers and acquisitions in 2019 in the text and Figure 1a have been modified to include 6 additional deals.

Supplementary Information

  1. Supplementary information

Competing Interests

The authors declare no competing interests.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links